These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 36191321)

  • 1. In migraine with previous treatment failures, eptinezumab safely reduced migraine days at 1 to 12 wk.
    Absher JR
    Ann Intern Med; 2022 Oct; 175(10):JC117. PubMed ID: 36191321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial.
    Ashina M; Lanteri-Minet M; Pozo-Rosich P; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
    Lancet Neurol; 2022 Jul; 21(7):597-607. PubMed ID: 35716692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of eptinezumab for migraine prevention in patients with prior preventive treatment failures: subgroup analysis of the randomized, placebo-controlled DELIVER study.
    Ashina M; Lanteri-Minet M; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B; Pozo-Rosich P
    Cephalalgia; 2023 May; 43(5):3331024231170807. PubMed ID: 37125484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of eptinezumab on self-reported work productivity in adults with migraine and prior preventive treatment failure in the randomized, double-blind, placebo-controlled DELIVER study.
    Barbanti P; Goadsby PJ; Lambru G; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
    J Headache Pain; 2022 Dec; 23(1):153. PubMed ID: 36460983
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effectiveness of eptinezumab in patients with migraine and prior preventive treatment failures: extension of a randomized controlled trial.
    Ashina M; Tepper SJ; Gendolla A; Sperling B; Ettrup A; Josiassen MK; Starling AJ
    J Headache Pain; 2023 Nov; 24(1):155. PubMed ID: 37985968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Immunogenicity Evaluation of Eptinezumab, a Therapeutic Humanized Monoclonal Antibody Targeting Calcitonin Gene-Related Peptide (CGRP) for the Preventive Treatment of Migraine.
    Pederson S; Biondi DM; Allan B; Cady R; Schaeffler B; Baker B; Latham J
    Front Immunol; 2021; 12():765822. PubMed ID: 34759933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24 weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study.
    Silberstein S; Diamond M; Hindiyeh NA; Biondi DM; Cady R; Hirman J; Allan B; Pederson S; Schaeffler B; Smith J
    J Headache Pain; 2020 Oct; 21(1):120. PubMed ID: 33023473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial.
    Mulleners WM; Kim BK; Láinez MJA; Lanteri-Minet M; Pozo-Rosich P; Wang S; Tockhorn-Heidenreich A; Aurora SK; Nichols RM; Yunes-Medina L; Detke HC
    Lancet Neurol; 2020 Oct; 19(10):814-825. PubMed ID: 32949542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial.
    Dodick DW; Lipton RB; Silberstein S; Goadsby PJ; Biondi D; Hirman J; Cady R; Smith J
    Cephalalgia; 2019 Aug; 39(9):1075-1085. PubMed ID: 31234642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eptinezumab improved patient-reported outcomes and quality of life in patients with migraine and prior preventive treatment failures.
    Goadsby PJ; Barbanti P; Lambru G; Ettrup A; Christoffersen CL; Josiassen MK; Phul R; Sperling B
    Eur J Neurol; 2023 Apr; 30(4):1089-1098. PubMed ID: 36583633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular outcomes in adults with migraine treated with eptinezumab for migraine prevention: pooled data from four randomized, double-blind, placebo-controlled studies.
    Smith TR; Spierings ELH; Cady R; Hirman J; Ettrup A; Shen V
    J Headache Pain; 2021 Nov; 22(1):143. PubMed ID: 34823467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study.
    Smith TR; Janelidze M; Chakhava G; Cady R; Hirman J; Allan B; Pederson S; Smith J; Schaeffler B
    Clin Ther; 2020 Dec; 42(12):2254-2265.e3. PubMed ID: 33250209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Intravenous Eptinezumab vs Placebo on Headache Pain and Most Bothersome Symptom When Initiated During a Migraine Attack: A Randomized Clinical Trial.
    Winner PK; McAllister P; Chakhava G; Ailani J; Ettrup A; Krog Josiassen M; Lindsten A; Mehta L; Cady R
    JAMA; 2021 Jun; 325(23):2348-2356. PubMed ID: 34128999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Responder rates with eptinezumab over 24 weeks in patients with prior preventive migraine treatment failures: post hoc analysis of the DELIVER randomized clinical trial.
    Ashina M; Lipton RB; Ailani J; Versijpt J; Sacco S; Mitsikostas DD; Christoffersen CL; Sperling B; Ettrup A
    Eur J Neurol; 2024 Feb; 31(2):e16131. PubMed ID: 37955557
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
    Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
    Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.
    Lipton RB; Goadsby PJ; Smith J; Schaeffler BA; Biondi DM; Hirman J; Pederson S; Allan B; Cady R
    Neurology; 2020 Mar; 94(13):e1365-e1377. PubMed ID: 32209650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2.
    Martin V; Nagy AJ; Janelidze M; Giorgadze G; Hirman J; Cady R; Mehta L; Buse DC
    Clin Ther; 2022 Mar; 44(3):389-402. PubMed ID: 35131090
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-identified most bothersome symptom in preventive migraine treatment with eptinezumab: A novel patient-centered outcome.
    Lipton RB; Dodick DW; Ailani J; McGill L; Hirman J; Cady R
    Headache; 2021 May; 61(5):766-776. PubMed ID: 34013992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1).
    Ashina M; Saper J; Cady R; Schaeffler BA; Biondi DM; Hirman J; Pederson S; Allan B; Smith J
    Cephalalgia; 2020 Mar; 40(3):241-254. PubMed ID: 32075406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of galcanezumab in patients with episodic migraine and a history of preventive treatment failure: results from two global randomized clinical trials.
    Ruff DD; Ford JH; Tockhorn-Heidenreich A; Stauffer VL; Govindan S; Aurora SK; Terwindt GM; Goadsby PJ
    Eur J Neurol; 2020 Apr; 27(4):609-618. PubMed ID: 31692188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.